Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Health Breach Notification Amendments Underscore Need For Federal Legislation, Expert Says

Executive Summary

Former deputy privacy director of HHS Deven McGraw spoke to Medtech Insight about the shortfalls of the FTC’s proposed health breach notification amendments.

You may also be interested in...



Regulatory And Commercial Should Be 'Hand In Hand' For Dx Success, Expert Says

Considering where and how a test will be used, and what kind of evidence regulators will want before clearing it, is key for developers of at home and point-of-care diagnostics.

FTC Health Breach Proposal Could Create Confusion For HIPAA Entities

Medtech Insight followed up with Invitae’s Deven McGraw about further possible confusion that could be caused by the Federal Trade Commission’s proposed amendments to the Health Breach Notification Requirements (HBNR).

News We’re Watching: May Health PCOS Treatment Shows Promise, Roche Adds Alzheimer’s Assays, Luciole Buys Spiegelberg

This week, May Health’s Ovarian Rebalancing showed promise as a treatment for polycystic ovarian syndrome; a trial of CathWorks’ FFRangio System launched; Roche introduced new assays for Alzheimer’s Disease; Early Health settled data breach allegations; and Boston Scientific added two new board members.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel